Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 12, 2020
Daily News
February 12, 2020
- PMDA to Set Up New Consultation Services for Continuous Manufacturing, Database Use
February 12, 2020
- In Japan Too, Pfizer and Mylan Prepping for Pending Viatris Integration
February 12, 2020
- With 2 New Deals Inked, Meiji Hunkering Down for Full-Scale Entry into Hematology Market
February 12, 2020
- FPMAJ Creates Scheme to Deal with Drug Supply Disruptions; Companies to Set Up “Supply Adjustment Teams”
February 12, 2020
- MHLW Urges Pharmacies to Limit Per-Customer Purchases for Face Masks, Sanitizer
February 12, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…